Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, c
Dr Rebecca Power, Postdoctoral Researcher at the Nutrition Research Centre Ireland, shared the role that CANTAB played in her latest publication: Targeted Nutritional Intervention for Patients with Mild Cognitive Impairment: The Cognitive impAiRmEnt Study (CARES) Trial 1
At AAIC 2019 we presented an interim analysis of online screening as a recruitment strategy for the MOPEAD initiative. The initial findings are positive, with high levels of engagement from older adults, as well as sensitivity to impairment.
At AAIC 2019, we shared how to administer and score verbal neuropsychological assessments on participants own devices in a way that is acceptable, feasible and reliable.
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
PhD researcher, Rosalyn Hithersay, spoke to us about her recent publication on which cognitive tests are most sensitive to the early stages of dementia in Down syndrome.
Neural Network classification of longitudinal cognitive data for prediction of individual-level chan
For the first time, Neural Network classifiers have been applied to changes in CANTAB PAL performance between baseline and 10 months to accurately predict the development of MCI at 20 months. Dr Elizabeth Baker, Statistical Scientist at Cambridge Cognition, presented the novel findings at AAIC 2018.
Cambridge Cognition presented new data at AAIC 2018 that demonstrates a demand from patients for the objective assessment of memory function, and describes how CANTAB testing can triage these memory complaints in clinic.
We are pleased to announce our partnership with Dementias Platform UK (DPUK), the world’s largest study group in dementia research formed to accelerate the development of effective, and ultimately preventative, treatments for diseases such as Alzheimer’s.
We’re pleased to announce that our CANTAB Recruit software is now established in two major Phase III trials into Alzheimer’s disease.
The latest FDA draft guidance for clinical trials in early Alzheimer’s disease presents many new opportunities and challenges for drug development.
Dr Kenton Zavitz, Director of Clinical Affairs at Cambridge Cognition, and Dr Robert Smith, Consultant Neuropsychologist, hosted a webinar to discuss clinical trials for early Alzheimer’s disease.
Join them to hear more about overcoming the barriers to expedite the drug development process.
Tuesday 22nd May 2018, 11 a.m. EDT
New data demonstrates possibility for speech recognition and online assessments to enhance clinical trials in Alzheimer’s disease.
Enriching participant eligibility for clinical trials through pre-screening for cognitive deficit.
Identifying participants in the ‘pre-clinical’ or ‘prodromal’ stage of Alzheimer's disease prior to the onset of cognitive and functional decline can be challenging, time-consuming and expensive. Can, pre-screening for episodic memory deficits enrich the recruitment of eligible participants in early Alzheimer’s disease clinical trials?
Showcasing a range of digital neurotechnologies to improve the research, diagnosis and treatment in Alzheimer's disease.
Computerised testing brings an unprecedented ability to capture more detailed information about patient responses. This could provide novel insights into cognitive processes, and greater discriminatory power in predicting cognitive deficits and decline in Alzheimer's and other diseases.
Exploring the use of automated voice based cognitive assessments on consumer voice platforms.
Cambridge Cognition is attending the Alzheimer's Association International Conference in London.
The early identification of individuals at risk of Alzheimer's Disease (AD) is of primary importance for the development of new effective interventions to stop the progression of the disease before the onset of severe neurodegeneration and clinical manifestations.